Verdict's In: Percutaneous Balloon Mitral Valvuloplasty Works Well

Article

Percutaneous balloon mitral valvulopasty (PMV) has now been around long enough for long term outcomes to be assessed. The verdict is positive.

Percutaneous balloon mitral valvulopasty (PMV) has now been around long enough for long-term outcomes to be assessed.

Reporting at the ESC Congress 2016 Ines Rodriges of Hospital de Santa Marta, Lisbon, Portugal, and colleagues reviews outcomes of patients who had the procedure to correct rheumatic mitral stenosis.

Of 213 consecutive patients who had PMV in a single center, from 1991 to 2 014, 89% had a successful PMV. During a mean followup period of 11.2 years, only 25.15% of patients had a major cardiac event. Of those 6.6% were deaths, 6.6% repeat PVM, and 21% mitral surgery.

Cumulative event-free survival at 20 years was 54.7%.

"Up to 20 years after successful PMV, a sizeable proportion of patients are event-free, which confirms the late efficacy of PMV," the team concluded.

"In our cohort, echocardiographic score before PMV was the only independent predictor of event-free survival," they added.

Previous studies have shown low technical failure and major complications with PMV, they noted.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Brendon Neuen, MBBS, PhD | Credit: X.com
© 2024 MJH Life Sciences

All rights reserved.